CU24325B1 - Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores - Google Patents
Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladoresInfo
- Publication number
- CU24325B1 CU24325B1 CUP2014000103A CU20140103A CU24325B1 CU 24325 B1 CU24325 B1 CU 24325B1 CU P2014000103 A CUP2014000103 A CU P2014000103A CU 20140103 A CU20140103 A CU 20140103A CU 24325 B1 CU24325 B1 CU 24325B1
- Authority
- CU
- Cuba
- Prior art keywords
- modulators
- disorders associated
- treat diseases
- calcium sensitive
- sensitive receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN178KO2012 | 2012-02-24 | ||
| IN1030KO2012 | 2012-09-07 | ||
| PCT/IB2013/051445 WO2013124828A1 (en) | 2012-02-24 | 2013-02-22 | Substituted chroman compounds as calcium sensing receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140103A7 CU20140103A7 (es) | 2015-01-29 |
| CU24325B1 true CU24325B1 (es) | 2018-03-13 |
Family
ID=54261188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000103A CU24325B1 (es) | 2012-02-24 | 2013-02-22 | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2864332C (en) * | 2012-02-24 | 2020-08-25 | Lupin Limited | Substituted chroman compounds as calcium sensing receptor modulators |
| IN2015MN00421A (en:Method) * | 2012-08-27 | 2015-09-04 | Lupin Ltd | |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| US9493396B2 (en) | 2013-08-28 | 2016-11-15 | Lupin Atlantis Holdings Sa | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| CA3158696A1 (en) | 2019-11-19 | 2021-05-27 | Lupin Limited | Process for preparing chroman compounds |
| EP4081210A1 (en) * | 2019-12-27 | 2022-11-02 | Lupin Limited | Pharmaceutical composition of casr modulators and methods and uses thereof |
| US12344592B2 (en) * | 2020-01-17 | 2025-07-01 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0020018B1 (en) * | 1979-05-19 | 1983-06-01 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| JPWO2004106280A1 (ja) | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
| US7585886B2 (en) | 2005-05-19 | 2009-09-08 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| TW200815388A (en) | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| EP2079739A2 (en) | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| CA2672956C (en) * | 2006-10-26 | 2015-02-10 | Amgen Inc. | Calcium receptor modulating agents |
| WO2008059854A1 (en) | 2006-11-16 | 2008-05-22 | Astellas Pharma Inc. | Piperidine derivatives or salts thereof |
| ES2476391T3 (es) * | 2007-10-15 | 2014-07-14 | Amgen Inc. | Agentes moduladores de receptor de calcio |
| MX2010005631A (es) | 2007-11-23 | 2010-06-02 | Leo Pharma As | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. |
| EP2345636B1 (en) | 2008-10-03 | 2016-03-30 | Ajinomoto Co., Inc. | Casr agonist |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
| WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| RU2013128950A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Замещенные циклопентилазины в качестве casr-активных соединений |
| WO2012069419A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| WO2012120476A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| EP2686306B1 (en) | 2011-03-18 | 2017-01-04 | Lupin Atlantis Holdings SA | Benzo[b][1,4]oxazin derivatives as calcium sensing receptor modulators |
| CA2864332C (en) * | 2012-02-24 | 2020-08-25 | Lupin Limited | Substituted chroman compounds as calcium sensing receptor modulators |
-
2013
- 2013-02-22 CA CA2864332A patent/CA2864332C/en active Active
- 2013-02-22 KR KR1020147025242A patent/KR102041154B1/ko active Active
- 2013-02-22 GE GEAP201313579A patent/GEP20186911B/en unknown
- 2013-02-22 ES ES13712928T patent/ES2743492T3/es active Active
- 2013-02-22 RS RSP20191101 patent/RS59172B1/sr unknown
- 2013-02-22 MX MX2014010139A patent/MX355670B/es active IP Right Grant
- 2013-02-22 PE PE2014001297A patent/PE20142281A1/es active IP Right Grant
- 2013-02-22 IN IN1672MUN2014 patent/IN2014MN01672A/en unknown
- 2013-02-22 SM SM20190506T patent/SMT201900506T1/it unknown
- 2013-02-22 BR BR112014021133-7A patent/BR112014021133B1/pt active IP Right Grant
- 2013-02-22 EP EP13712928.4A patent/EP2817299B1/en active Active
- 2013-02-22 NZ NZ628627A patent/NZ628627A/en unknown
- 2013-02-22 CU CUP2014000103A patent/CU24325B1/es unknown
- 2013-02-22 PL PL13712928T patent/PL2817299T3/pl unknown
- 2013-02-22 CN CN201380021510.0A patent/CN104350047B/zh active Active
- 2013-02-22 HR HRP20191606 patent/HRP20191606T1/hr unknown
- 2013-02-22 MY MYPI2014702272A patent/MY171374A/en unknown
- 2013-02-22 AP AP2014007919A patent/AP2014007919A0/xx unknown
- 2013-02-22 SG SG11201405117SA patent/SG11201405117SA/en unknown
- 2013-02-22 PT PT13712928T patent/PT2817299T/pt unknown
- 2013-02-22 DK DK13712928.4T patent/DK2817299T3/da active
- 2013-02-22 WO PCT/IB2013/051445 patent/WO2013124828A1/en not_active Ceased
- 2013-02-22 EA EA201491582A patent/EA026940B9/ru unknown
- 2013-02-22 SI SI201331561T patent/SI2817299T1/sl unknown
- 2013-02-22 AU AU2013223715A patent/AU2013223715B2/en active Active
- 2013-02-22 US US14/380,632 patent/US9163001B2/en active Active
- 2013-02-22 UA UAA201410409A patent/UA112679C2/uk unknown
- 2013-02-22 LT LTEP13712928.4T patent/LT2817299T/lt unknown
- 2013-02-22 JP JP2014558258A patent/JP6114316B2/ja active Active
- 2013-02-22 HU HUE13712928A patent/HUE046172T2/hu unknown
- 2013-02-23 TW TW102106358A patent/TWI617549B/zh not_active IP Right Cessation
- 2013-02-25 AR ARP130100556A patent/AR090135A1/es active IP Right Grant
-
2014
- 2014-08-14 TN TNP2014000352A patent/TN2014000352A1/fr unknown
- 2014-08-15 ZA ZA2014/05990A patent/ZA201405990B/en unknown
- 2014-08-20 PH PH12014501891A patent/PH12014501891B1/en unknown
- 2014-08-20 CL CL2014002218A patent/CL2014002218A1/es unknown
- 2014-08-21 NI NI201400094A patent/NI201400094A/es unknown
- 2014-08-21 DO DO2014000193A patent/DOP2014000193A/es unknown
- 2014-08-21 IL IL234252A patent/IL234252A/en active IP Right Grant
- 2014-08-22 GT GT201400179A patent/GT201400179A/es unknown
- 2014-09-10 MA MA37344A patent/MA35937B1/fr unknown
- 2014-09-17 CR CR20140424A patent/CR20140424A/es unknown
- 2014-09-23 CO CO14210706A patent/CO7160018A2/es unknown
-
2015
- 2015-09-01 US US14/842,141 patent/US9598391B2/en active Active
-
2017
- 2017-01-26 US US15/416,684 patent/US9987249B2/en active Active
-
2019
- 2019-09-10 CY CY20191100947T patent/CY1122017T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24325B1 (es) | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores | |
| GT201400275A (es) | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huèrfano rory | |
| UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CR20150255A (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
| GT201500024A (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| NI201900076A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CR20110455A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| CO7160047A2 (es) | Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr) | |
| CO2019007882A2 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| CL2017000818A1 (es) | Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii | |
| PH12013501899A1 (en) | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators | |
| GT201000170A (es) | Derivados de ciclopropilamina | |
| DOP2010000079A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 | |
| CR11309A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonista de la histamnia-3 | |
| BR112017009629A2 (pt) | triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2 | |
| CO6821958A2 (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2 | |
| UY33231A (es) | Aminotiazolonas como moduladores de los receptores de estrógenos alfa | |
| EA200970662A1 (ru) | Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора | |
| PA8827501A1 (es) | Pirrolidin amidas sustituidas como moduladores del receptor histamina h3 | |
| IN2015MN00421A (en:Method) | ||
| CU20100045A7 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 | |
| CU20100047A7 (es) | Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3 |